 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
|
Analyst Conference Summaries
Vertex Pharmaceuticals
VRTX
conference date: November 4, 2024 @ 1:30 PM Pacific Time
Vertex Pharmaceuticals for Strong CF Franchise Growth [Seeking Alpha, March 20, 2023]
Vertex Pharmaceuticals: Expect Growth [Seeking Alpha, December 20, 2022]
Vertex Pharmaceuticals Poised For Long-Term Growth [Seeking Alpha, February 2, 2021]
Vertex Pharmaceuticals Is (Now) A Good Long-Term Investment [Seeking Alpha, June 26, 2019]
Analyst Call Notes by William P. Meyers |
|||
| 2024 | |||
| Vertex Q1 2024 |
Vertex Q2 2024 |
Vertex Q3 2024 |
|
| May 6, 2024 | Aug. 1, 2024 | Nov. 4, 2024 | |
| 2023 | |||
| Vertex Q1 2023 |
Vertex Q2 2023 |
Vertex Q3 2023 |
Vertex Q4 2023 |
| May 1, 2023 | Aug. 1, 2023 | Nov. 6, 2023 | Feb. 5, 2024 |
| 2022 | |||
| Vertex Q1 2022 |
Vertex Q2 2022 |
Vertex Q3 2022 |
Vertex Q4 2022 |
| May 5, 2022 | Aug. 4, 2022 | Oct. 27, 2022 | Feb. 7, 2023 |
| 2021 | |||
| Vertex Q1 2021 |
Vertex Q2 2021 |
Vertex Q3 2021 |
Vertex Q4 2021 |
| April 29, 2021 | July 29, 2021 | Nov. 2, 2021 | Jan. 26, 2022 |
| 2020 | |||
| Vertex Q1 2020 |
Vertex Q2 2020 |
Vertex Q3 2020 |
Vertex Q4 2020 |
| April 29, 2020 | July 30, 2020 | Oct. 29, 2020 | Feb. 1, 2021 |
| 2019 | |||
| Vertex Q1 2019 |
Vertex Q2 2019 |
Vertex Q3 2019 |
Vertex Q4 2019 |
| April 30, 2019 | July 31, 2019 | Oct. 30, 2019 | Jan. 30, 2020 |
2018 |
|||
| Vertex Q4 2018 |
|||
May 26, 2018 |
July 25, 2018 |
Oct. 24, 2018 |
Feb. 5, 2019 |
2017 |
|||
April 27, 2016 |
July 26, 2017 |
Oct. 25, 2017 |
January 31, 2018 |
2016 |
|||
04/27/2016 |
07/27/2016 |
10/25/2016 |
01/25/2017 |
2015 |
|||
04/29/2015 |
07/29/2014 |
10/28/2015 |
01/27/2016 |
2014 |
|||
05/01/2014 |
07/29/2014 |
10/28/2014 |
01/28/2015 |
2013 |
|||
07/29/2013 |
10/29/2013 |
01/29/2014 |
|
The $300,000 Drug [New York Times, July 18, 2014]
I Still Don't Like Vertex [June 24, 2014]
Vertex Pharmaceuticals: Dog Of The Nasdaq 100? [September 11, 2013]
Vertex Pharmaceuticals (VRTX) is a manufacturer of therapies for Cystic Fibrosis and other diseases.
Vertex Pharmaceuticals web site
Vertex Pharmaceuticals investor relations page
I bought an initial small interest in August 2022.
More Analyst Conference Pages:
| AGEN |
| AGIO |
| ALLO |
| ALNY |
| AMAT |
| AMGN |
| APRE |
| ARWR |
| BIIB |
| BLRX |
| BLUE |
| BMY |
| CDTX |
| CLDX |
| FATE |
| GILD |
| GLYC |
| ILMN |
| INCY |
| INO |
| IONS |
| MCHP |
| PLX |
| REGN |
| RNA |
| SAGE |
| SANA |
| SYRS |
| TSVT |
| VRTX |
| WBA |
Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. This is financial journalism, not investment advice
Copyright 2024 William P. Meyers